TT 223 + Epidermal growth factor analogue

Drug Profile

TT 223 + Epidermal growth factor analogue

Alternative Names: E1-I.N.T™; G1 + EGF analogue; TT-223 + EGF; TT-223 + EGF analogue

Latest Information Update: 27 Sep 2010

Price : $50

At a glance

  • Originator Transition Therapeutics
  • Class Antihyperglycaemics; Gastrointestinal hormones; Growth factors; Neuropeptides; Peptide hormones
  • Mechanism of Action Epidermal growth factor stimulants; Gastrin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Type 1 diabetes mellitus; Type 2 diabetes mellitus

Most Recent Events

  • 17 Sep 2010 Discontinued - Phase-II for Type-1 diabetes mellitus in USA (SC)
  • 17 Sep 2010 Discontinued - Phase-II for Type-2 diabetes mellitus in USA (SC)
  • 14 Mar 2008 Transition Therapeutics and Eli Lilly enter into a licensing and collaboration agreement for gastrin-based therapies in Diabetes
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top